Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations.
about
Perphenazine for schizophreniaManagement of sexual dysfunction due to antipsychotic drug therapyHaloperidol dose for the acute phase of schizophreniaPerphenazine for schizophreniaManagement of sexual dysfunction due to antipsychotic drug therapyNovel antipsychotics: issues and controversies. Typicality of atypical antipsychotics.Haloperidol dose for the acute phase of schizophrenia.Estimating reliability and generalizability from hierarchical biomedical data.Generalizability in nongaussian longitudinal clinical trial data based on generalized linear mixed models.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia.A comparative review of new antipsychotics.Body weight gain induced by antipsychotic drugs: mechanisms and management.Efficacy and safety of atypical antipsychotic drugs (quetiapine, risperidone, aripiprazole and paliperidone) compared with placebo or typical antipsychotic drugs for treating refractory schizophrenia: overview of systematic reviews.Conventional versus novel antipsychotics: changing concepts and clinical implicationsPlacebo response in antipsychotic clinical trials: a meta-analysis.World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance.Definition, psychopharmacological basis and clinical evaluation of novel/atypical neuroleptics: methodological issues and clinical consequences.Risperidone: a review.Risperidone-induced photosensitivity.Are second generation antipsychotics a distinct class?Dropout rates in randomized clinical trials of antipsychotics: a meta-analysis comparing first- and second-generation drugs and an examination of the role of trial design featuresSecond-generation antipsychotics for schizophrenia: can we resolve the conflict?Risperidone in the treatment of psychosis; a concise review.Investigating the criterion validity of psychiatric symptom scales using surrogate marker validation methodology.Atypical antipsychotics. Part I: Pharmacology, pharmacokinetics, and efficacy.Risperidone in the treatment of schizophrenia: a meta-analysis of randomized controlled trials.Risperidone for schizophrenia.A double-blind randomized trial between risperidone and haloperidol in drug-naive patients with paranoid schizophrenia.Antipsychotic drug-induced obesity in rats: correlation between leptin, insulin and body weight during sulpiride treatment.Risperidone (Risperdal): clinical experience with a new antipsychosis drug.Risperidone: treatment response in adult and geriatric patients.Retention rates in placebo- and nonplacebo-controlled clinical trials of schizophrenia.Pharmacological Treatment for Long-Term Patients with Schizophrenia and Its Effects on Sleep in Daily Clinical Practice: A Pilot Study.
P2860
Q24187359-BBE3FB27-6305-4B97-9167-FAC96D6913CEQ24197558-B4576413-D00B-434D-9ABF-61B0D671DB34Q24200200-6632DF6E-B3D8-4718-94A5-852FBC39DD23Q24245109-BBD02FD5-CDF4-43BB-998C-4529AFD86B8EQ24246362-058DE89D-FFE9-42E0-81F6-5093698014C3Q30501297-5D697EFF-EA48-48C5-B172-0FD73A819569Q30838771-E526BE81-E5E0-4354-8A2A-F880211A7128Q31117818-7E357666-70BD-487A-965D-096FB28DDCD1Q31161878-6DACE13D-EB75-4BC3-855A-25D41F31C2CCQ33223628-EB76458D-552A-4123-8C79-B8678AA13334Q33606079-B17E16EE-C76E-4D7F-90B9-FB29D18818C7Q33708467-6A4C486D-FE30-4EC2-AD09-5D2DFEA65208Q33724292-28B2EAAE-A098-4F29-9F71-86A8D54524F0Q33787546-19A52C32-0BCC-422A-8F2C-2A649238097BQ34443837-385A9DC4-D588-46A8-9DEC-12BD601456AEQ34640811-E28DBB68-44ED-4792-AAAC-D7AFBC3EB2CDQ35073807-AB1C0B0C-B841-4D49-A817-CA9D8DA7DE47Q36150794-CB36A595-3DB5-4BF5-B85D-99C1E0DD783EQ36612833-EF79124A-722A-42B8-BE5D-B2ABCC5171DCQ36784527-91E74802-2DC8-4017-A34D-EE58CFD4F2F6Q37227479-857082D9-45F0-470C-8A53-BDC62F55DF51Q37428125-51AF21D1-AA63-48AB-A91F-58F3453D4DF8Q38769247-764116AF-4962-4240-B2DE-ACA1F076F472Q40623665-217E0AF9-31EE-4D24-9219-673F8F2E1046Q40824970-3749A84F-3D0D-4E70-8D54-859AB73DC174Q42550256-87E5AB6F-B792-4FE8-8F8D-C65EB5852B0AQ42581589-7E3DE930-78E6-4F22-8E25-4A4F361B203FQ46545005-135C7544-7230-40BE-AD9D-6158DAF474C6Q47247035-66087D70-1807-4884-9E90-5FE627B10905Q51928464-05B10EDD-A32E-4B65-BA0A-4ACBCB567A00Q51991635-EB1E915E-7A80-49E6-A4CE-656CB85AC8EEQ52172787-14036B73-80DA-410C-9726-F453793BA7A6Q55424943-1427BBE8-4B49-49DF-87BF-3DCC419A4441
P2860
Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations.
description
1993 nî lūn-bûn
@nan
1993 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1993 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
name
Risperidone versus perphenazin ...... ents with acute exacerbations.
@ast
Risperidone versus perphenazin ...... ents with acute exacerbations.
@en
Risperidone versus perphenazin ...... ents with acute exacerbations.
@nl
type
label
Risperidone versus perphenazin ...... ents with acute exacerbations.
@ast
Risperidone versus perphenazin ...... ents with acute exacerbations.
@en
Risperidone versus perphenazin ...... ents with acute exacerbations.
@nl
prefLabel
Risperidone versus perphenazin ...... ents with acute exacerbations.
@ast
Risperidone versus perphenazin ...... ents with acute exacerbations.
@en
Risperidone versus perphenazin ...... ents with acute exacerbations.
@nl
P2093
P1476
Risperidone versus perphenazin ...... ents with acute exacerbations.
@en
P2093
Høyberg OJ
Salvesen I
Sloth-Nielsen M
P304
P356
10.1111/J.1600-0447.1993.TB03480.X
P407
P577
1993-12-01T00:00:00Z